Last reviewed · How we verify
BN104
At a glance
| Generic name | BN104 |
|---|---|
| Sponsor | BioNova Pharmaceuticals (Shanghai) LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of BN104 in the Treatment of Acute Leukemia (PHASE1, PHASE2)
- The Effect of Food on the Pharmacokinetics of BN104 Tablets (PHASE1)
- Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia (PHASE2)
- BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BN104 CI brief — competitive landscape report
- BN104 updates RSS · CI watch RSS
- BioNova Pharmaceuticals (Shanghai) LTD. portfolio CI